Au HCT, Zheng YJ, Le GH, Wong S, Phan L, Teopiz KM, Kwan ATH, Rhee TG, Rosenblat JD, Ho R, McIntyre RS (2025) A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders
However, severe side effects may require more immediate medical attention
there is no dietitian access
Your healthcare provider may decide to stop your XIGDUO XR for a while if you have any of these things
Provide right medicines Prescriptions are complex documents
Advanced Recomp Stack vs common alternatives Feature Components Advanced Recomp Stack Retatrutide + CJC-1295 (No DAC) + Ipamorelin CagriSema Cagrilintide + Semaglutide Retatrutide Solo Retatrutide only Reta + MOTS-c Retatrutide + MOTS-c Feature Receptor targets Advanced Recomp Stack GLP-1 + GIP + Glucagon + GHRH + Ghrelin CagriSema GLP-1 + Amylin Retatrutide Solo GLP-1 + GIP + Glucagon Reta + MOTS-c GLP-1 + GIP + Glucagon + mitochondrial Feature GH-axis support Advanced Recomp Stack Yes CagriSema No Retatrutide Solo No Reta + MOTS-c No Feature Peak weight loss Advanced Recomp Stack ~29% from retatrutide + theoretical lean preservation CagriSema ~22-24% Phase 3 Retatrutide Solo ~29% Phase 3 Reta + MOTS-c ~29% from reta